Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avichai Shimoni

Showing results (71-80 of 165) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|February 10, 2021
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cellsTalya Wittmann Dayagi, Gilad Sherman, Bella Bielorai, et al.
European Journal of Haematology|November 13, 2013
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patientsMaya Koren-Michowitz, Zehavit Buzaglo, Elena Ribakovsky, et al.
Bone Marrow Transplantation|August 30, 2019
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosisRoni Shouval, Yakov Vega, Joshua A Fein, et al.
British Journal of Haematology|August 23, 2012
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allograftingEvgeny Klyuchnikov, Ernst Holler, Martin Bornhäuser, et al.
Journal of Hematology & Oncology|October 10, 2022
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progressionKatia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, et al.
British Journal of Haematology|October 29, 2021
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipientsNoga Shem-Tov, Ronit Yerushalmi, Ivetta Danylesko, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantationArnon Nagler, Raanan Berger, Aliza Ackerstein, et al.
Bone Marrow Transplantation|October 26, 2018
Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host diseaseIvetta Danylesko, Adomas Bukauskas, Martin Paulson, et al.
Blood|August 5, 2004
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myelomaNicolaus Kröger, Avichai Shimoni, Maria Zagrivnaja, et al.
Annals of Hematology|October 10, 2021
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective studyOren Pasvolsky, Shai Shimony, Ron Ram, et al.
Pageof 17

Showing results (71-80 of 165) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|February 10, 2021
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cellsTalya Wittmann Dayagi, Gilad Sherman, Bella Bielorai, et al.
European Journal of Haematology|November 13, 2013
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patientsMaya Koren-Michowitz, Zehavit Buzaglo, Elena Ribakovsky, et al.
Bone Marrow Transplantation|August 30, 2019
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosisRoni Shouval, Yakov Vega, Joshua A Fein, et al.
British Journal of Haematology|August 23, 2012
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allograftingEvgeny Klyuchnikov, Ernst Holler, Martin Bornhäuser, et al.
Journal of Hematology & Oncology|October 10, 2022
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progressionKatia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, et al.
British Journal of Haematology|October 29, 2021
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipientsNoga Shem-Tov, Ronit Yerushalmi, Ivetta Danylesko, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantationArnon Nagler, Raanan Berger, Aliza Ackerstein, et al.
Bone Marrow Transplantation|October 26, 2018
Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host diseaseIvetta Danylesko, Adomas Bukauskas, Martin Paulson, et al.
Blood|August 5, 2004
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myelomaNicolaus Kröger, Avichai Shimoni, Maria Zagrivnaja, et al.
Annals of Hematology|October 10, 2021
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective studyOren Pasvolsky, Shai Shimony, Ron Ram, et al.
Pageof 17